pneumococcal conjugate vaccine
Direct Comparison of Immunogenicity Induced by 10- or 13-Valent Pneumococcal Conjugate Vaccine around the 11-Month Booster in Dutch Infants.
... invasive pneumococcal dis- ease ...7-valent pneumococcal conjugate vaccine (PCV7) for infants in the Netherlands dramatically decrease SP carriage and IPD for its seven serotypes [4–10], in ...
16
Cost-Effectiveness of Vaccinating Immunocompetent ≥65 Year Olds with the 13-Valent Pneumococcal Conjugate Vaccine in England.
... in vaccine arm vs 3 in the placebo arm) ...PCV13 vaccine types due to the herd immunity impact of the 10– valent PCV childhood vaccination programme introduced in the Netherlands in 2011 and which covered ...
14
Correction: Direct Comparison of Immunogenicity Induced by 10- or 13-Valent Pneumococcal Conjugate Vaccine around the 11-Month Booster in Dutch Infants.
... 1. Wijmenga-Monsuur AJ, van Westen E, Knol MJ, Jongerius RMC, Zancolli M, Goldblatt D, et al. (2015) Direct Comparison of Immunogenicity Induced by 10- or 13-Valent Pneumococcal Conjugate Vaccine ...
1
Temporal changes in nasopharyngeal carriage of Streptococcus pneumoniae serotype 1 genotypes in healthy Gambians before and after the 7-valent pneumococcal conjugate vaccine
... invasive pneumococcal disease surveillance studies in The Gambia such as IPD surveillance in the Upper River Region (Mackenzie et ...the pneumococcal disease surveillance in the West Africa region ...
11
Nasopharyngeal carriage and transmission of Streptococcus pneumoniae in American Indian households after a decade of pneumococcal conjugate vaccine use.
... A NP specimen refers to a single sample from an individual; an isolate refers to a pneumococcal strain, specified by its serotype identified from a swab. A carriage episode refers to the isolation of a serotype ...
8
The serotype distribution among healthy carriers before vaccination is essential for predicting the impact of pneumococcal conjugate vaccine on invasive disease.
... 7-valent pneumococcal conjugate vaccination on invasive pneumococcal disease, as measured by incidence rate ratios (IRR), has recently been summa- rized from country specific IPD disease rate ...
15
Vacinas Pneumocócicas
... of pneumococcal vaccines are licensed to prevent invasive pneumococcal disease (IPD), both targeting a restricted number of serotypes out of the 94 serotypes currently recognized in Streptococcus ...
11
Human Infant Memory B Cell and CD4+ T Cell Responses to HibMenCY-TT Glyco-Conjugate Vaccine.
... glyco-conjugate vaccine, and to determine the influence of these cells on IgG ...of Pneumococcal conjugate vaccine in adults showed that CRM 197 carrier protein-specific ...
18
Theoretical pneumococcal vaccine coverage: analysis of serotypes isolated from inpatients at a tertiary care hospital
... 13-valent pneumococcal conjugate vaccine (PCV13) and the 23-valent pneumococcal polysaccharide vaccine ...yielded pneumococcal isolates. The theoretical vaccine coverage ...
6
Progress towards meningitis prevention in the conjugate vaccines era
... a pneumococcal conjugate ...valent conjugate vaccine for American children under 2 years ...this vaccine contains only 7 serotypes – 4, 6B, 9V, 14, 18C, 19F and 23F, but these are ...
10
J. Pediatr. (Rio J.) vol.88 número1 en a16v88n01
... 9. Grijalva CG, Nuorti JP, Arbogast PG, Martin SW, Edwards KM, Grifin MR. Decline in pneumonia admissions after routine childhood immunisation with pneumococcal conjugate vaccine in the USA: a ...
2
Dominance of vaccine serotypes in pediatric invasive pneumococcal infections in Portugal (2012–2015)
... 13-valent pneumococcal conjugate vaccine (PCV13) use in the private market (uptake of 61%) in pediatric invasive pneumococcal disease (pIPD) in Portugal ...
9
Antibody response to pneumococcal capsular polysaccharide vaccine in Down syndrome patients
... 23-valent pneumococcal poly- saccharide vaccines for use among children over 2 years of age who had a high risk of pneumococcal disease, including those with chronic underlying diseases or who were ...
6
Avaliação da efetividade da vacina antipneumocócica 10 valente na redução da doença pneumocócica invasiva em crianças brasileiras : estudo caso controle multicêntrico
... of pneumococcal conjugate vaccine in national immunization programs has a key role in the prevention of diseases caused by ...of pneumococcal conjugate 10 valent vaccine (PCV-10) ...
152
Cad. Saúde Pública vol.31 número2
... The use of secondary data in epidemiologi- cal studies can pose limitations, prone to biases, ranging from case capture to data entry. In addi- tion, ecological analyses are not indicated for de- termining causality, ...
9
J. Pediatr. (Rio J.) vol.82 número3 suppl. en v82n3sa02
... the vaccines high immunogenicity (approximately ...this vaccine if it is given before 1 year of ...this vaccine universal from 1 year on and reducing the age of administration from 2 years to 1 ...
11
Predictors of Uptake and Timeliness of Newly Introduced Pneumococcal and Rotavirus Vaccines, and of Measles Vaccine in Rural Malawi: A Population Cohort Study.
... of vaccine coverage for PCV13 and RV1 since reported cov- erage was lower among children without ...increased vaccine uptake. Although vaccine uptake may be higher in our Demographic Surveillance ...
15
The role of co-colonization in pneumococcal ecology and evolution
... Our study has some limitations. First, we did not sequence individual genes in the locus. Given this, the strains that had apparently intact blpA genes but lacked pheromone secretion may have been inactive due to ...
187
A Seroepidemiological Study of Serogroup A Meningococcal Infection in the African Meningitis Belt.
... and conjugate vaccines has been studied in the African meningitis belt[7–10] on several occasions but there have been few studies of population levels of antibody to ...gate vaccine, MenAfriVac™, to ...
12
Multiple colonization with S. pneumoniae before and after introduction of the seven-valent conjugated pneumococcal polysaccharide vaccine.
... for pneumococcal evolution through horizontal exchange of genes, which may result in the acquisition of antibiotic resistance or capsule switch ...the vaccine era as in the prevaccine era and new strains ...
8